President Donald Trump announced Tuesday that US Space Command will be relocated from Colorado to Alabama, returning to the Pentagon's plans for the command's headquarters from the final days of Trump's first term in the White House.

The headquarters will move to the Army's Redstone Arsenal in Huntsville, Alabama. Trump made the announcement in the Oval Office, flanked by Republican members of the Alabama congressional delegation.

The move will "help America defend and dominate the high frontier," Trump said. It also marks another twist on a contentious issue that has pitted Colorado and Alabama against one another in a fight for the right to be home to the permanent headquarters of Space Command (SPACECOM), a unified combatant command responsible for carrying out military operations in space.

Read full article

Comments

President Donald Trump announced Tuesday that US Space Command will be relocated from Colorado to Alabama, returning to the Pentagon's plans for the command's headquarters from the final days of Trump's first term in the White House.

The headquarters will move to the Army's Redstone Arsenal in Huntsville, Alabama. Trump made the announcement in the Oval Office, flanked by Republican members of the Alabama congressional delegation.

The move will "help America defend and dominate the high frontier," Trump said. It also marks another twist on a contentious issue that has pitted Colorado and Alabama against one another in a fight for the right to be home to the permanent headquarters of Space Command (SPACECOM), a unified combatant command responsible for carrying out military operations in space.

Read full article

Comments

President Donald Trump announced Tuesday that US Space Command will be relocated from Colorado to Alabama, returning to the Pentagon's plans for the command's headquarters from the final days of Trump's first term in the White House.

The headquarters will move to the Army's Redstone Arsenal in Huntsville, Alabama. Trump made the announcement in the Oval Office, flanked by Republican members of the Alabama congressional delegation.

The move will "help America defend and dominate the high frontier," Trump said. It also marks another twist on a contentious issue that has pitted Colorado and Alabama against one another in a fight for the right to be home to the permanent headquarters of Space Command (SPACECOM), a unified combatant command responsible for carrying out military operations in space.

Read full article

Comments

Dolby has announced the features of Dolby Vision 2, its successor to the popular Dolby Vision HDR format.

Whereas the original Dolby Vision was meant to give creators the ability to finely tune exactly how TVs present content in HDR, Dolby Vision 2 appears to significantly broaden that feature to include motion handling as well—and it also tries to bridge the gap between filmmaker intent and the on-the-ground reality of the individual viewing environments.

What does that mean, exactly? Well, Dolby says one of the pillars of Dolby Vision 2 will be "Content Intelligence," which introduces new "AI capabilities" to the Dolby Vision spec. Among other things, that means using sensors in the TV to try to fix the oft-complained-about issue of shows being too dark.

Read full article

Comments

Dolby has announced the features of Dolby Vision 2, its successor to the popular Dolby Vision HDR format.

Whereas the original Dolby Vision was meant to give creators the ability to finely tune exactly how TVs present content in HDR, Dolby Vision 2 appears to significantly broaden that feature to include motion handling as well—and it also tries to bridge the gap between filmmaker intent and the on-the-ground reality of the individual viewing environments.

What does that mean, exactly? Well, Dolby says one of the pillars of Dolby Vision 2 will be "Content Intelligence," which introduces new "AI capabilities" to the Dolby Vision spec. Among other things, that means using sensors in the TV to try to fix the oft-complained-about issue of shows being too dark.

Read full article

Comments

Dolby has announced the features of Dolby Vision 2, its successor to the popular Dolby Vision HDR format.

Whereas the original Dolby Vision was meant to give creators the ability to finely tune exactly how TVs present content in HDR, Dolby Vision 2 appears to significantly broaden that feature to include motion handling as well—and it also tries to bridge the gap between filmmaker intent and the on-the-ground reality of the individual viewing environments.

What does that mean, exactly? Well, Dolby says one of the pillars of Dolby Vision 2 will be "Content Intelligence," which introduces new "AI capabilities" to the Dolby Vision spec. Among other things, that means using sensors in the TV to try to fix the oft-complained-about issue of shows being too dark.

Read full article

Comments

Daily squirts of a safe, over-the-counter allergy nasal spray may prevent COVID-19 infections from taking hold, according to results published Tuesday in JAMA Internal Medicine . In a mid-staged trial, the spray appeared to reduce infections by promising 67 percent, though a larger trial will need to confirm that robust efficacy.

The trial was a randomized, double-blind, placebo-controlled Phase 2 trial conducted by researchers at Germany's Saarland University between March 2023 and July 2024. The study included 450 healthy adults, about half of whom (227) spritzed their noses three times a day with the generic antihistamine nasal spray, azelastine, which can be purchased over the counter in the US. The placebo, meanwhile, was a spray with an identical composition except for the absence of the antihistamine. The two groups had similar mixes of previous COVID-19 vaccination and infection statuses.

After about 56 days of frequent mistings, only five people using the allergy spray (2.2 percent) caught a SARS-CoV-2 infection, while 15 people using a placebo (6.7 percent) got the pandemic infection. That 4.5 percentage-point drop represents a 67 percent reduction in COVID-19 cases, though the numbers here are small. Still, the researchers noted that the five people using the allergy spray who contracted COVID-19 took more time to get the infection than the 15 in the placebo group (31 days versus 19.5). This could hint that the spray held off some infections from exposures early in the trial. And when the allergy spray users did get COVID-19, they were positive on a rapid antigen test for less time than those infected in the placebo group (3.4 days versus 5.1 days), suggesting they cleared the virus a bit faster.

Read full article

Comments

Daily squirts of a safe, over-the-counter allergy nasal spray may prevent COVID-19 infections from taking hold, according to results published Tuesday in JAMA Internal Medicine . In a mid-staged trial, the spray appeared to reduce infections by promising 67 percent, though a larger trial will need to confirm that robust efficacy.

The trial was a randomized, double-blind, placebo-controlled Phase 2 trial conducted by researchers at Germany's Saarland University between March 2023 and July 2024. The study included 450 healthy adults, about half of whom (227) spritzed their noses three times a day with the generic antihistamine nasal spray, azelastine, which can be purchased over the counter in the US. The placebo, meanwhile, was a spray with an identical composition except for the absence of the antihistamine. The two groups had similar mixes of previous COVID-19 vaccination and infection statuses.

After about 56 days of frequent mistings, only five people using the allergy spray (2.2 percent) caught a SARS-CoV-2 infection, while 15 people using a placebo (6.7 percent) got the pandemic infection. That 4.5 percentage-point drop represents a 67 percent reduction in COVID-19 cases, though the numbers here are small. Still, the researchers noted that the five people using the allergy spray who contracted COVID-19 took more time to get the infection than the 15 in the placebo group (31 days versus 19.5). This could hint that the spray held off some infections from exposures early in the trial. And when the allergy spray users did get COVID-19, they were positive on a rapid antigen test for less time than those infected in the placebo group (3.4 days versus 5.1 days), suggesting they cleared the virus a bit faster.

Read full article

Comments

Daily squirts of a safe, over-the-counter allergy nasal spray may prevent COVID-19 infections from taking hold, according to results published Tuesday in JAMA Internal Medicine . In a mid-staged trial, the spray appeared to reduce infections by promising 67 percent, though a larger trial will need to confirm that robust efficacy.

The trial was a randomized, double-blind, placebo-controlled Phase 2 trial conducted by researchers at Germany's Saarland University between March 2023 and July 2024. The study included 450 healthy adults, about half of whom (227) spritzed their noses three times a day with the generic antihistamine nasal spray, azelastine, which can be purchased over the counter in the US. The placebo, meanwhile, was a spray with an identical composition except for the absence of the antihistamine. The two groups had similar mixes of previous COVID-19 vaccination and infection statuses.

After about 56 days of frequent mistings, only five people using the allergy spray (2.2 percent) caught a SARS-CoV-2 infection, while 15 people using a placebo (6.7 percent) got the pandemic infection. That 4.5 percentage-point drop represents a 67 percent reduction in COVID-19 cases, though the numbers here are small. Still, the researchers noted that the five people using the allergy spray who contracted COVID-19 took more time to get the infection than the 15 in the placebo group (31 days versus 19.5). This could hint that the spray held off some infections from exposures early in the trial. And when the allergy spray users did get COVID-19, they were positive on a rapid antigen test for less time than those infected in the placebo group (3.4 days versus 5.1 days), suggesting they cleared the virus a bit faster.

Read full article

Comments